| Document |
Document Title |
|
WO/2023/246858A1 |
The present disclosure relates to a pharmaceutical salt of a borate derivative, and a crystallization form and use thereof. In particular, the present disclosure provides a pharmaceutical salt of a compound represented by formula (I), an...
|
|
WO/2023/241683A1 |
Provided in the present invention are a PDE4B inhibitor and the use thereof. Specifically, provided in the present invention are a nitrogen-containing heterocyclic compound as represented by formula (II), or a tautomer, a stereoisomer, a...
|
|
WO/2023/243855A1 |
The present invention relates to a composition including a Daihong Crataegus pinnatifida Bunge extract as an active ingredient for improving gut health or treating inflammatory bowel disease. The Daihong Crataegus pinnatifida Bunge extra...
|
|
WO/2023/243934A1 |
The present invention relates to a composition comprising primed functionally-enhanced stem cells for preventing, ameliorating or treating arthritis, a stem cell therapeutic agent, and a method for preparing same. Stem cells primed by tr...
|
|
WO/2023/240379A1 |
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, ste...
|
|
WO/2023/242605A1 |
The invention relates to algal extracellular vesicles (EVs) for use in therapy and in restoring or maintaining health of a subject. In particular the invention relates to uses of algal EVs in therapy, wherein the EVs themselves have favo...
|
|
WO/2023/243166A1 |
The present invention addresses the problem of effectively promoting granulation in a dermal defect or a subcutaneous tissue defect caused by a severe burn. To solve this problem, provided is a cell to be used for treating a burn, said c...
|
|
WO/2023/241140A1 |
The present invention relates to the technical field of biological medicine, particularly to use of a class of substituted diaryl compounds in the preparation of anti-inflammatory drugs. The compounds have a structure represented by form...
|
|
WO/2023/241699A1 |
The present disclosure relates to a cyclopentyl adenosine derivative and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, whe...
|
|
WO/2023/241608A1 |
The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.
|
|
WO/2023/242339A1 |
The subject matter of the present invention relates to a composition having hepatoprotective effect and comprising petasin and isopetasin, its use as dietary food item, food supplement, medicinal product, pharmaceutical composition or dr...
|
|
WO/2023/241023A2 |
Provided in the present invention is a novel phase-change adjusting kit, comprising at least two independent components which can interact with each other to specifically drive themselves and cell surface molecules combined thereon to ge...
|
|
WO/2023/244547A1 |
Antibodies with improved affinity for integrin avB8 and uses thereof are provided.
|
|
WO/2023/245086A1 |
Compositions, methods, and kits of small molecular weight agents can bind and stimulate the Fc-γ-activating receptors to enhance humoral immune-response and immune-effector cell response by improving immune-effector cell and/or antibody...
|
|
WO/2023/240678A1 |
Disclosed are a polyketone compound with an anti-inflammatory activity, and a preparation method therefor and the use thereof. The method comprises: isolating Penicillium endophytic fungus (Penicillium sp.) HJT-A-10 from a root slice col...
|
|
WO/2023/241684A1 |
Provided in the present invention are a compound as represented by formula II, or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The compound has a good PDE4B inhibition effect.
|
|
WO/2023/240679A1 |
The present invention relates to the technical field of medicines, and disclosed are a pair of polyketide compounds having anti-inflammatory activity, a preparation method therefor, and a use thereof. Specifically, endophytic fungus Alte...
|
|
WO/2023/236485A1 |
Disclosed are artemisinin derivatives, a preparation method therefor, and the uses thereof. The structural formula of the artemisinin derivatives is represented by formula I. The compounds have suitable solubility and are relatively stab...
|
|
WO/2023/236809A1 |
The present invention belongs to the technical field of anti-inflammatory drugs. Disclosed are a 2,6-dibenzylidene cyclohexanone oxime compound, a method for preparing same, and use thereof. According to the present invention, a structur...
|
|
WO/2023/236945A1 |
The present invention provides a pyridazin-3-carboxamide compound of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, raceme, solvate, hydrate, polymorphic form, prodrug, or isotopic variant thereof. ...
|
|
WO/2023/236797A1 |
Disclosed in the present invention are a hangtaimycin derivative, a preparation method therefor, and the use thereof. The hangtaimycin derivative is prepared by performing fermentation in an SFMR culture medium by using Streptomyces spec...
|
|
WO/2023/240081A1 |
Provided herein are methods of treating, ameliorating, and/or preventing inflammatory diseases or disorders by administering to an afflicted subject a composition comprising ornithine, or a derivative thereof. Also provided are methods o...
|
|
WO/2023/237015A1 |
The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl...
|
|
WO/2023/240134A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
|
WO/2023/240069A1 |
Disclosed herein are compositions comprising mesenchymal stromal cell-derived extracellular vesicle-associated miRNAs (MSC-EV-miRNAs) and their use in subjects diagnosed with acute respiratory distress syndrome (ARDS) and other inflammat...
|
|
WO/2023/239842A1 |
Described herein are vaginal lactobacilli strains that actively modulate mucosal immunity, and compounds produced by these bacteria that exhibit anti-inflammatory activity.
|
|
WO/2023/237675A1 |
The present invention relates to vitamin B2 (riboflavin) for use in improving gut health in animals and humans. In particular, it was found that vitamin B2, upon delivery to the large intestine, increases the abundance of the beneficial ...
|
|
WO/2023/237686A1 |
The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when de...
|
|
WO/2023/236924A1 |
Provided are a biphenyl compound, a pharmaceutical composition, a method for preparing same, and use thereof. The biphenyl compound has a structure represented by formula I. The provided biphenyl compound can have relatively good binding...
|
|
WO/2023/236199A1 |
The present invention relates to a crystal of an N-(benzoyl)-phenylalanine compound and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof. Specifically, the compound is as represented by formula ...
|
|
WO/2023/239200A1 |
The present invention relates to: a thermo-sensitive poly(organophosphazene) polymer loaded with a drug; a pharmaceutical composition for preventing or treating inflammatory diseases, comprising same; and the like. An injectable polymer ...
|
|
WO/2023/236345A1 |
The present application relates to a genetic engineering drug for treating inflammatory arthritis and a preparation method therefor. Specifically, the present application provides a use of an A20 protein or a functional active fragment t...
|
|
WO/2023/239941A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed ...
|
|
WO/2023/238065A1 |
Small molecule inhibitors of Nav1.8 voltage-gated sodium ion channel, including compounds of formula (I), (II), (III), (IV), and (V) are described. Also described are pharmaceutical compositions containing a compound of formula (I), (II)...
|
|
WO/2023/237753A1 |
The present disclosure relates to crystalline forms of norketamine, in particular norketamine hydrochloride, processes for the preparation and uses thereof.
|
|
WO/2023/240259A1 |
Various inflammatory conditions result in increased lnterleukin-6 (IL-6) levels in the human body. The present invention relates to methods of treating a variety of inflammatory conditions that results in increased lnterleukin-6 (IL-6) l...
|
|
WO/2023/237049A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating IRAK4 inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparati...
|
|
WO/2023/237116A1 |
The present invention discloses a protein degrader such as a GSPT1 degrader and use thereof, particularly use in the prevention and/or treatment of diseases.
|
|
WO/2023/237681A1 |
The present invention relates to a combination comprising vitamin C and Bifidobacterium animalis ssp. lactis and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Bifidobacterium ani...
|
|
WO/2023/239213A1 |
An inflammatory cell-specific drug delivery system (CDC fusion protein) according to the present invention, which is based on a fusion protein of ubiquitin protein and caspase-1 recognition sequence, does not function in normal cells as ...
|
|
WO/2023/236241A1 |
The present invention relates to the technical field of traditional Chinese medicines, and in particular, to a medium for analgesic moxibustion with seed-sized moxa cones and a method for preparing same. Specifically, the present inventi...
|
|
WO/2023/232997A1 |
The invention relates to a synergistic multi-ionic complex providing potentiated preventive and therapeutic responses to inflammation by modulating the pathways of immunity. It is a composition comprising mineral salts, including at leas...
|
|
WO/2023/232123A1 |
Provided are a sesquiterpene polyketone compound, a pharmaceutical composition, and use thereof as an immunomodulator and in preventing and treating immune diseases. Biological activity assay shows that the sesquiterpene polyketone compo...
|
|
WO/2023/233791A1 |
Provided are: an integrin activator that contains a substance that inhibits binding between a fibronectin and an immune inhibitory receptor LILRB4 as an active ingredient; and a therapeutic agent that contains a substance that inhibits b...
|
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/233570A1 |
The purpose of the present invention is to provide: a composition for treating acute rhinitis and allergic rhinitis; use of the same; and a method for treating acute rhinitis and allergic rhinitis. Specifically, the present invention per...
|
|
WO/2023/235738A1 |
The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.
|
|
WO/2023/233183A1 |
The present invention relates to the field of medicaments. Particularly, the present invention refers to the combination of cannabidiol (CBD) and resveratrol at a specific dosage regimen and related application with "entourage effect-lik...
|
|
WO/2023/233033A1 |
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors, which renders these compounds highly advantageous for use...
|
|
WO/2023/233665A1 |
Provided are: an immunocyte activator containing, as an active ingredient, a substance which inhibits the binding of fibronectin and an immunosuppressive receptor LILRB4; and a therapeutic agent for immunocyte-related inflammatory diseas...
|
